ERBB2 and breast carcinoma: HER2 amplification is a marker of an aggressive tumor phenotype and before the advent of trastuzumab patients with HER2-positive (HER2+) breast cancer had a poor prognosis and shorter survival compared with those whose tumors did not overexpress HER2 [4–6].